SURMOUNT 2 Trial Results and Potential Role of Tirzepatide in Treating Obesity in Type 2 Diabetes
Friday, June 23, at 3:45 p.m. PT
Ballroom 20A-C
San Diego Convention Center
(Livestream Available)
Presentation: Tirzepatide and the Rationale, Pharmacology, and Mechanism of Multifunctional Peptides
Matthias H. Tschöp, MD
Professor,
Helmholtz Munich
What is your presentation about?
Tirzepatide and the rationale, pharmacology, and mechanism of multifunctional peptides.
What makes this topic important in 2023?
The discovery of these classes of highly effective anti-obesity drugs represents a transformative change for metabolic medicine.
How did you become involved with this area of diabetes research or care?
I started 30 years ago as a physician scientist in endocrinology and diabetology — seeing a lot of obese patients. I became rapidly frustrated with the fact that we had no effective (and safe) obesity therapeutic to offer. As a consequence, I left clinical medicine and pursued discovery of novel and more effective anti-obesity therapeutics.
How do you think your presentation will impact diabetes research or care?
Based on these discoveries and their clinical validation, scientists as well as clinicians will change the way they are approaching the study as well as the treatment of obesity and diabetes.
What are you most looking forward to at the 83rd Scientific Sessions?
Reconnecting with colleagues and discussing the dynamic developments in the field that happened over the last year.